Levamlodipine/valsartan - Ahn-Gook Pharmaceuticals

Drug Profile

Levamlodipine/valsartan - Ahn-Gook Pharmaceuticals

Alternative Names: AGSAV-301; S-amlodipine/valsartan; Valsartan/levamlodipine - Ahn-Gook Pharmaceuticals; Valsartan/S-amlodipine

Latest Information Update: 03 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ahn-Gook Pharmaceutical
  • Class Antihypertensives; Branched-chain amino acids; Dihydropyridines; Nicotinic-acids; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Hypertension

Most Recent Events

  • 03 Mar 2016 No development reported - Phase-I for Hypertension (In volunteers) in South Korea (PO)
  • 31 Oct 2013 Pharmacokinetics and adverse event data from a phase I trial in Healthy volunteers released by Ahn-Gook Pharmaceutical
  • 21 Feb 2012 Phase-I clinical trials in Hypertension (in volunteers) in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top